- Home
- SCPH vs TIL Comparison
SCPH vs TIL Comparison
Compare SCPH & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- TIL
- Stock Information
- Founded
- SCPH 2013
- TIL 2018
- Country
- SCPH United States
- TIL United States
- Employees
- SCPH N/A
- TIL N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- SCPH Health Care
- TIL Health Care
- Exchange
- SCPH Nasdaq
- TIL Nasdaq
- Market Cap
- SCPH 173.6M
- TIL 171.7M
- IPO Year
- SCPH 2017
- TIL 2021
- Fundamental
- Price
- SCPH $3.25
- TIL $22.12
- Analyst Decision
- SCPH Strong Buy
- TIL Strong Buy
- Analyst Count
- SCPH 2
- TIL 4
- Target Price
- SCPH $15.00
- TIL $114.00
- AVG Volume (30 Days)
- SCPH 267.8K
- TIL 83.9K
- Earning Date
- SCPH 03-12-2025
- TIL 03-20-2025
- Dividend Yield
- SCPH N/A
- TIL N/A
- EPS Growth
- SCPH N/A
- TIL N/A
- EPS
- SCPH N/A
- TIL N/A
- Revenue
- SCPH $30,278,000.00
- TIL N/A
- Revenue This Year
- SCPH $172.27
- TIL N/A
- Revenue Next Year
- SCPH $131.75
- TIL N/A
- P/E Ratio
- SCPH N/A
- TIL N/A
- Revenue Growth
- SCPH 303.87
- TIL N/A
- 52 Week Low
- SCPH $3.08
- TIL $9.62
- 52 Week High
- SCPH $6.54
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- SCPH 43.27
- TIL 48.67
- Support Level
- SCPH $3.09
- TIL $19.00
- Resistance Level
- SCPH $3.87
- TIL $25.80
- Average True Range (ATR)
- SCPH 0.20
- TIL 2.19
- MACD
- SCPH 0.00
- TIL 0.22
- Stochastic Oscillator
- SCPH 20.65
- TIL 45.88
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.